{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:41:09Z","timestamp":1762299669068,"version":"3.44.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.lfs.2021.119136","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T09:34:09Z","timestamp":1611740049000},"page":"119136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["S3-2, a novel long-lasting oxyntomodulin derivative, exerts improvement on diabesity and renal injury through activating GLP-1 and glucagon receptors"],"prefix":"10.1016","volume":"270","author":[{"given":"Peng","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingzhang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhua","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianjun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.lfs.2021.119136_bb0005","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc10-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","author":"Association AD","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2021.119136_bb0010","first-page":"111","article-title":"Molecular mechanisms of insulin resistance in type 2 diabetes mellitus","volume":"107","author":"Saini","year":"2010","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.lfs.2021.119136_bb0015","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1001\/jama.288.20.2579","article-title":"Molecular understanding of hyperglycemia's adverse effects for diabetic complications","volume":"288","author":"Sheetz","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.lfs.2021.119136_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000115118","article-title":"Hyperglycemia and the pathobiology of diabetic complications","volume":"45","author":"Aronson","year":"2008","journal-title":"Adv. Cardiol."},{"key":"10.1016\/j.lfs.2021.119136_bb0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejps.2006.01.003","article-title":"GLP-1 based therapy for type 2 diabetes","volume":"28","author":"Arulmozhi","year":"2006","journal-title":"European Journal of Pharmaceutical Sciences Official Journal of the European Federation for Pharmaceutical Sciences."},{"key":"10.1016\/j.lfs.2021.119136_bb0030","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2217\/dmt.13.41","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes","volume":"3","author":"Bo","year":"2013","journal-title":"Diabetes Management."},{"key":"10.1016\/j.lfs.2021.119136_bb0035","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fnins.2015.00092","article-title":"GLP-1 based therapeutics: simultaneously combating T2DM and obesity","volume":"9","author":"Heppner","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.lfs.2021.119136_bb0040","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/175045891202200404","article-title":"Treatment and management of obesity: is surgical intervention the answer?","volume":"22","author":"Cobbold","year":"2012","journal-title":"Journal of Perioperative Practice."},{"key":"10.1016\/j.lfs.2021.119136_bb0045","first-page":"1151","article-title":"The mechanism of action for oxyntomodulin in the regulation of obesity","volume":"11","author":"Wynne","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.lfs.2021.119136_bb0050","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/00024677-200605050-00001","article-title":"Oxyntomodulin","volume":"5","author":"Druce","year":"2006","journal-title":"Treat. Endocrinol."},{"key":"10.1016\/j.lfs.2021.119136_bb0055","first-page":"9","article-title":"Oxyntomodulin\u2014a novel treatment for human obesity","volume":"1","author":"Lofthouse","year":"2005","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2021.119136_bb0060","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.molmet.2013.12.001","article-title":"Action and therapeutic potential of oxyntomodulin","volume":"3","author":"Pocai","year":"2014","journal-title":"Molecular Metabolism."},{"key":"10.1016\/j.lfs.2021.119136_bb0065","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1210\/jc.2015-2335","article-title":"Effect of oxyntomodulin, glucagon, GLP-1 and combined glucagon + GLP-1 infusion on food intake, appetite and resting energy expenditure","volume":"100","author":"Bagger","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.lfs.2021.119136_bb0070","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4155\/tde.14.117","article-title":"Pulmonary delivery of anorectic oxyntomodulin in rats: food intake suppression, reduced body weight gain and pharmacokinetics","volume":"6","author":"Nadkarni","year":"2015","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.lfs.2021.119136_bb0075","first-page":"270","article-title":"DPP-IV-resistant, long-acting oxyntomodulin derivatives","volume":"17","author":"Santoprete","year":"2011","journal-title":"Journal of Peptide Science An Official Publication of the European Peptide Society."},{"key":"10.1016\/j.lfs.2021.119136_bb0080","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1021\/acschembio.5b00787","article-title":"Design of Potent and Proteolytically Stable Oxyntomodulin Analogs","volume":"11","author":"Muppidi","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.lfs.2021.119136_bb0085","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/sj.ijo.0803344","article-title":"Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial","volume":"30","author":"Wynne","year":"2006","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.lfs.2021.119136_bb0090","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/prot.23234","article-title":"Novel high-affinity binders of human interferon gamma derived from albumin-binding domain of protein G","volume":"80","author":"Ahmad","year":"2012","journal-title":"Proteins-structure Function & Bioinformatics."},{"key":"10.1016\/j.lfs.2021.119136_bb0095","first-page":"39","article-title":"Human serum albumin as carrier in drug delivery systems","volume":"136","author":"Ishima","year":"2016","journal-title":"Yakugaku Zasshi Journal of the Pharmaceutical Society of Japan."},{"key":"10.1016\/j.lfs.2021.119136_bb0100","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/protein\/gzn028","article-title":"Engineering of a femtomolar affinity binding protein to human serum albumin","volume":"21","author":"Jonsson","year":"2008","journal-title":"Protn Engineering Design & Selection."},{"key":"10.1016\/j.lfs.2021.119136_bb0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40591-016-0048-8","article-title":"Albumin-based drug delivery: harnessing nature to cure disease","volume":"4","author":"Larsen","year":"2016","journal-title":"Molecular & Cellular Therapies."},{"key":"10.1016\/j.lfs.2021.119136_bb0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1066896913517939","article-title":"KC. The wonderful colors of the hematoxylin-eosin stain in diagnostic surgical pathology","volume":"22","author":"Chan","year":"2014","journal-title":"Int. J. Surg. Pathol."},{"key":"10.1016\/j.lfs.2021.119136_bb0115","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/B0-08-045044-X\/00050-X","article-title":"Peptide and protein drugs: issues and solutions","volume":"2","author":"Nestor","year":"2007","journal-title":"Comprehensive Medicinal Chemistry II."},{"key":"10.1016\/j.lfs.2021.119136_bb0120","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1039\/C0MD00111B","article-title":"Strategies to prolong the plasma residence time of peptide drugs","volume":"1","author":"Pollaro","year":"2010","journal-title":"Medchemcommun."},{"key":"10.1016\/j.lfs.2021.119136_bb0125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/156720107780362339","article-title":"Recent advances in protein and peptide drug delivery systems","volume":"4","author":"Kumar Malik","year":"2007","journal-title":"Curr Drug Deliv."},{"key":"10.1016\/j.lfs.2021.119136_bb0130","doi-asserted-by":"crossref","first-page":"38118","DOI":"10.1074\/jbc.M405155200","article-title":"Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification","volume":"279","author":"Tsubery","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2021.119136_bb0135","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/bip.22474","article-title":"A GLP-1 receptor agonist conjugated to an albumin-binding domain for extended half-life","volume":"102","author":"Lindgren","year":"2014","journal-title":"Biopolymers."},{"key":"10.1016\/j.lfs.2021.119136_bb0140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.domaniend.2016.10.005","article-title":"Oxyntomodulin analog and exendin-4 derivative lower plasma glucose in cattle","volume":"59","author":"ThanThan","year":"2017","journal-title":"Domest. Anim. Endocrinol."},{"key":"10.1016\/j.lfs.2021.119136_bb0145","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1248\/bpb.25.695","article-title":"Practical aspects of the ligand-binding and enzymatic properties of human serum albumin","volume":"25","author":"Kragh-Hansen","year":"2002","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.lfs.2021.119136_bb0150","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1023\/A:1015396825274","article-title":"Pharmaceutical strategies utilizing recombinant human serum albumin","volume":"19","author":"Chuang","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.lfs.2021.119136_bb0155","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrd3148","article-title":"Liraglutide","volume":"9","author":"Drucker","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2021.119136_bb0160","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1517\/14712598.2010.481281","article-title":"Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes","volume":"10","author":"St Onge","year":"2010","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.lfs.2021.119136_bb0165","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/psc.1328","article-title":"DPP-IV-resistant, long-acting oxyntomodulin derivatives","volume":"17","author":"Santoprete","year":"2011","journal-title":"J. Pept. Sci."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521001211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521001211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:43:59Z","timestamp":1758401039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320521001211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":33,"alternative-id":["S0024320521001211"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119136","relation":{},"ISSN":["0024-3205"],"issn-type":[{"type":"print","value":"0024-3205"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"S3-2, a novel long-lasting oxyntomodulin derivative, exerts improvement on diabesity and renal injury through activating GLP-1 and glucagon receptors","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"119136"}}